Objective The aim of this study was to assess changes in the trend of breast cancer mortality in Navarre, and the effect that a screening programme may have had on these changes. Methods A breast cancer screening programme targeting women aged 45-65 years was launched in Navarre in September 1990. Breast cancer deaths between 1975 and 2004 were identified from the Navarre Mortality Registry, and the date of diagnosis was obtained by linkage with the populationbased Navarre Cancer Registry. We compared breast cancer mortality during the pre-screening (1987-89) and screening (2002-04) periods, and with the estimated rate in the last period calculated by a linear model with a Poisson distribution. The long-term trends (from 1975 through 2004) were described by joinpoint regression analysis. Prevalent cases (those diagnosed before 1991) were excluded to minimize dilution of the benefit in the post-screening period due to deaths from tumours diagnosed before screening began. Results The joinpoint analysis showed a rising trend in breast cancer mortality rates until 1994, followed by a continual decrease of just over 5% per year. A comparison of mortality rates between the last pre-screening and the screening periods showed a decrease of 36% (95% confidence interval [CI] 21-48%), with the largest reduction in the 50-69 years age group (52%; CI: 33-65%). In this age group, mortality in the 2002-04 period was 62% lower than that projected from extrapolation of the pre-screening trend, while in unscreened age groups (30-44 and X75 years), mortality was only 22% lower. When prevalent tumours were excluded, the 50-69 years age group presented a further decrease in mortality than when all tumours were considered. Conclusions Fourteen years after the introduction of a screening programme, a major reduction in breast cancer mortality has been observed.
INTRODUCTION
I n 2004, breast cancer was the most common incident form of cancer in women (29% of all incident cases), and was the leading cause of cancer death (17.4% of the total) in the European Union. 1 Between 1973 and 1997, breast cancer incidence rose 30% in Western nations, where breast screening programmes were implemented in the late 1980s and early 1990s. 2 Although breast cancer incidence is on the rise worldwide, breast cancer mortality has either remained stable or declined in most countries. 2 A number of randomized studies have shown that screening programmes reduce mortality in the 50-69 years age group. 3, 4 Several other trend analyses and comparisons of mortality in populations before and after the introduction of screening programmes have highlighted their impact. This effect is maintained even after allowing for the contribution of other factors, 5, 6 such as treatment advances, more widespread use of mammography, and greater accessibility to tests that permit early diagnostic confirmation in women not included in screening programmes, thus leading to earlier diagnoses in these groups as well.
The aim of this study is to assess possible changes in the trend of mortality from breast cancer in Navarre and the effect that the screening programme may have had on these changes.
MATERIAL AND METHODS
In September 1990, a breast cancer screening programme was launched in Navarre (Spanish region of nearly 600,000 inhabitants), targeting all women aged 45-65 years. The initiative was included as a pilot programme in the European Breast Cancer Screening Network. In 1998, the age range was extended to 69 years. The first (prevalent) round was completed in two years, the period established as the screening interval, which has been maintained in subsequent rounds. The performance indicators (participation, detection rates, characteristics of the tumours detected, etc.) calculated throughout the programme 7-9 have consistently exceeded the reference values established by the European Union for breast cancer screening programmes. 10 Breast cancer deaths between 1975 and 2004 were identified from the Navarre Mortality Registry, which contains information on all deaths within the region, as well as those of residents who die outside the region. Deaths were coded according to the version of the International Classification of Diseases (ICD) in use in Spain at the time they occurred, the ICD-9 until 1998 and the ICD-10 from the beginning of 1999. Mortality rates were calculated using mid-year population estimates provided by the Navarre Statistics Institute for each year of the study period.
To compare the mortality trend in Navarre with that of Spain, the latest national data published for 1981-2003 were used.
The date of diagnosis of breast cancer deaths was obtained by linkage with the population-based Navarre Cancer Registry. At the time of this study, all incident cases of cancer from 1973 to 2001 had been recorded in this registry.
The analysis by age focuses on women aged 50-69 years, a group in which all of the deceased women have been invited to participate in the programme, although linkage with the screening database revealed that, during the whole screening period, just over 50% of cases were diagnosed before their inclusion in the programme. For purposes of comparison, the analysis also includes cases diagnosed in women who would not have been covered by the screening programme because they belonged to birth cohorts that were either too young (30-44 years) or too old (X75 years) to be included at the time the programme was launched.
The rates were standardized to the European population using the direct method. The confidence intervals (CIs) were calculated according to the method of Armitage and Berry. 11 To increase stability, three-or five-year rates and three-year moving averages were used in some analyses.
The long-term trends (i.e. from 1975 through 2004) in cancer mortality were described by joinpoint regression analysis, which involves fitting a series of joined straight lines on a log scale to the age-adjusted rates. 12 Line segments are joined at points called joinpoints. Each line segment is described by an annual percent change, which is based on the slope of the line segment, and each joinpoint denotes a statistically significant change in trend. The overall statistical significance was set at Po0.05, and a maximum of three joinpoints and four line segments were allowed. This type of analysis was applied to the overall adjusted rates and to the three age groups considered.
Breast cancer mortality rates up to 1995, the year in which there was a significant change in the trend, were included in a linear model with a Poisson distribution. The expected mortality rate in the 2002-04 period for the different age groups was calculated using this model. The expected and observed values were compared only for the overall rate and for the age group most involved in the programme (50-69 years) versus those not affected by it (30-44 and X75 years).
To minimize dilution of the benefit in the screening period due to deaths from tumours diagnosed before screening began, we excluded women with breast cancer diagnosed before 1991, the first full year in which the programme was conducted. After excluding these cases, in the last five-year post-screening period (1997) (1998) (1999) (2000) (2001) , the percentage of deaths in women who had a malignant tumour prior to the first invitation fell to 9% in the 50-69 years age group. The mortality rate in this period (1997) (1998) (1999) (2000) (2001) was compared with that observed in the final pre-screening period (1986) (1987) (1988) (1989) (1990) , also after excluding all cases diagnosed prior to 1980. The relative risk (RR) of mortality between the two periods was obtained, with the 95% CIs calculated by Smith's method 11 for both the overall rate and the rate in each age group.
The joinpoint analyses were performed using the 'Joinpoint' software from the Surveillance Research Program of the US National Cancer Institute (available at http:// srab.cancer.gov/joinpoint). The mortality estimates for 2002-04 were made using SAS 8.2. All other calculations were made using SPSS-12.0S for Windows. Table 1 shows the number of deaths from breast cancer and the crude and age-adjusted mortality rates for 1975-2004, with their standard errors. As shown on Figure 1 , the adjusted mortality rates showed an upward trend until the 1993-95 period when they peaked, followed by a decline in subsequent years. The mortality rate in 2002-04 represented a 36% reduction (95% CI 21-48%) compared with the prescreening period (1987-89), and a 40% reduction (95% CI 27-51%) in relation to the peak rate in 1993-95. Figure 2 represents the time trend by age groups. The reduction in the 50-69 years age group was 52% (CI 95% 33-65%) for 2002-04 compared with the pre-screening period, and was 55% lower (CI 95% 38-68%) than in 1993-95. The unscreened groups (30-44 and X75 years) showed decreases of different magnitude with respect to this period, although neither reached levels of statistical significance.
RESULTS

Evolution of observed mortality rates
The results of the joinpoint regression analysis revealed two patterns with respect to the evolution of overall mortality: a non-significant increase in mortality of 1.2% per year up to 1994, followed by a statistically significant decline of 5.3% per annum ( Table 2 ). The decrease was much greater, 9.0% per annum, in the 50-69 years age group, the one most likely to have participated in the screening programme. No statistically significant trends were observed in the other age groups. Table 3) . 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 
Comparison of observed and modelled mortality rates
Evolution of mortality rates excluding prevalent cancers
Comparison of trends observed in Navarre and Spain
From 1981 until the 1993-1995 period, breast cancer mortality in both Navarre and all of Spain showed a rising trend, with higher rates seen in Navarre ( Figure 5 ). The rates subsequently began to decline, practically in parallel, in both Navarre and Spain until 1997. The reduction in Navarre then became more pronounced, with the mortality rate in the final period falling to 17.5 per 100,000 (95% CI 15.5-19.5), significantly lower than the national rate of 20.8 per 100,000 (95% CI 20.5-21.0).
DISCUSSION
Mortality rates from breast cancer in Navarre presented a rising trend until the 1993-95 period. Subsequently, a continual decrease of just over 5% per year was observed -from 26.6 per 100,000 population in 1993-95 to 15.9 per 100,000 in 2002-04, more than 10 years after the screening programme began. A comparison of the mortality rate observed before (1987-89) and after the start of the programme (2002-04) reveals a decline of 36%. A simple before-and-after comparison could be biased due to the contribution of factors external to the programme: more widespread use of mammography, the use of tamoxifen and other adjuvant chemotheraphy, as well as greater access to diagnostic tests and treatment. 5 It is difficult to quantify the effect of each of these factors. Depending on the statistical model used, the proportion of the reduction attributable to screening varies widely, ranging from 28% to 65% in the United States of America. 6 Nonetheless, it is important to point out that the largest decrease in mortality in our study was seen in women in the 50-69 years age group -those most involved in the screening programme -although this decline cannot be attributed exclusively to screening. The reduction in this age group reached a level of 9% per year, whereas no 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 Navarre Spain
Year statistically significant modification in mortality was seen in those groups not affected by the programme. The magnitude of this reduction would support the hypothesis that the screening programme is responsible for a large part of the reduced mortality in the women most likely to have benefitted from it. Furthermore, in comparison to projected mortality rates based on linear extrapolation, the observed mortality rate in the two age groups not affected by the screening programme was only about 22% lower, whereas the rate in the 50-69 years age group was a full 62% lower. The results of the mortality analysis in periods relatively close to the time the programme began could be influenced by the inclusion of prevalent cases, which can dilute the effect, as other authors have pointed out. In Navarre, it was possible to compare the observed changes in mortality after excluding these previously diagnosed cases. When the mortality rates in the last period of the screening programme are compared with those of the pre-screening period, the reduction in mortality is more pronounced than when all cases are considered, which confirms the proposed theory. According to this analysis, the risk of dying from breast cancer in Navarre was significantly lower in the 50-69 years age group (0.58), women among whom the programme could have had the greatest impact. The unscreened age groups (30-44 and X75 years) presented risks slightly greater than 1.
Regardless of whether overall mortality or the specific mortality of the most exposed groups is studied, the decrease observed in Navarre is high and greater than in some randomized clinical trials and evaluations of screening programmes. In the 1990s, reductions in mortality rates from breast cancer were reported in several countries, 13 although they tend to be lower than those observed in Navarre. In the United States of America, a 2.3% per annum decrease in the 30-79 years age group was observed in the 1990-2002 period, 14 very similar to the 2.1% reported in Spain for the total population in the 1992-2000 period. 15 Randomized clinical trials in Sweden showed a decrease in mortality of around 21% in women invited to attend a screening programme. The benefit began to emerge approximately four years after randomization and continued to increase up to around 10 years. 16 Evaluation studies performed in populations where screening programmes are available show great variability, with reductions between 6% and 63%, depending on the methodology used. 17 The Copenhagen programme showed a 25% reduction in mortality in the 50-79 years age group in the screening period compared with an historical period, and a 37% reduction when considering only women who were actually screened. 18 An evaluation in England and Wales after a short follow-up period and without excluding prevalent cancers estimated a 21% decrease in the 50-64 years age group, a third of which were attributed to screening. 19 In The Netherlands, and also without excluding prevalent cancers, there was a 20% reduction in the group included in the screening programme. 17 A study conducted in two Swedish counties found reductions in mortality of between 40% and 50%, which the authors considered greater than the benefits observed in randomized screening trials. 20 Reductions in mortality of up to 40% have also been reported in areas of the province of Florence (Italy), where screening started in the 1970s. 21 The screening programme in Navarre was implemented very rapidly. In two years, it covered the entire population, and over time participation rates of more than 85% have been achieved. Over 95% of women who enter the programme continue to participate, and thus practically all subsequent examinations are within the recommended twoyear interval, which entails a great likelihood of impact on the population.
The initial impact estimates made for Navarre 22,23 predicted a large decrease in mortality, explained by the rapid implementation of the programme and high participation rate that has been maintained over the years. As indicated by the same study, the clinical stage of breast cancers diagnosed immediately prior to programme implementation in Navarre tended to be more unfavourable than those diagnosed in regions of some other European countries. Consequently, the screening programme was more likely to detect cancers at an earlier stage and thus have a greater impact on case fatality.
Mortality from breast cancer fell in practically all regions of Spain following the 1991-95 period, despite the fact that some regional screening programmes had only recently been launched. 15, 24 The general introduction of new neoadjuvant therapies at the end of the 1980s, and specifically, the systematic use of tamoxifen, might explain this reduction. The same reasons might explain the reduced mortality in Navarre in the 1993-95 period, given that the screening programme was launched just two years earlier. However, mortality after that period declined considerably more in Navarre than at the national level, providing further evidence that the observed decrease in mortality is, to a large extent, due to the screening programme. Given that the Navarre programme was the first to be launched in Spain, it is likely that earlier and more intense declines in mortality will be observed in this region.
In conclusion, our evaluation of the screening programme in Navarre reveals major reductions in breast cancer mortality, both in the overall population and in the screening group. These results show, once again, the important effect that breast cancer screening programmes can have on mortality from this tumour.
